Ingersoll Rand delivered a strong finish to 2025, with Q4 revenue increasing 10% year-over-year (3% organic) and Adjusted EPS rising 14% to $0.96. For the full year, revenue grew 6% to approximately $7.6 billion (implied) with Adjusted EBITDA of $2.1 billion, representing a 27.4% margin, and Adjusted EPS of $3.34 (up 2%). The company demonstrated robust M&A execution, investing $525 million across 16 transactions, while recurring revenue exceeded $450 million with a $1.1 billion backlog. Looking ahead to 2026, management issued conservative guidance with revenue growth of 2.5%-4.5% (1% organic at midpoint) and EPS of $3.45-$3.57, citing tariff headwinds in the first half and no immediate macro recovery baked into the numbers.
| Metric | Value | Change |
|---|---|---|
| Q4 Revenue | Up 10% YoY | +3% Organic |
| Q4 Adjusted EBITDA | $580 million | 27.7% Margin |
| Q4 Adjusted EPS | $0.96 | +14% YoY |
| FY 2025 Revenue | Up 6% YoY | -1% Organic |
| FY 2025 Adjusted EBITDA | $2.1 billion | 27.4% Margin |
| FY 2025 Adjusted EPS | $3.34 | +2% YoY |
| Recurring Revenue | $450 million | Backlog $1.1B |
| Book-to-Bill (Q4) | 0.93 turns | N/A |
| Free Cash Flow (Q4) | $462 million | N/A |
Management emphasized the durability of their 'M&A flywheel' as a core growth engine, deploying $525 million across 16 transactions in 2025 at an average 9x presynergy multiple. This strategy is not just additive but transformative, with nine deals already under LOI for 2026 and the recent Synomics acquisition enhancing their life sciences portfolio. The focus on 'bolt-on' acquisitions allows for rapid integration and technology cross-pollination, such as combining U.S. acquired technologies with local manufacturing in China to drive share gains.
Recurring revenue has emerged as a critical strategic pillar, growing from $200 million two years ago to over $450 million in 2025, with a backlog of $1.1 billion. This shift improves revenue quality and predictability, with margins reportedly north of 60%. Management views this as a 'clear demonstration' of progress toward long-term targets, leveraging service technicians and digital solutions to convert installed bases into high-margin annuity streams.
Ingersoll Rand is successfully executing a 'self-help' strategy in China, a market that has been challenging for many industrials. By localizing technologies acquired in the U.S. and Europe and launching new products like high-efficiency blowers, the company achieved three consecutive quarters of organic order growth in China. This demonstrates their ability to gain share and grow even in a flat or down macro environment, reducing reliance on broad regional recovery.
The company is prioritizing capital allocation flexibility, maintaining leverage well under 2x while aggressively returning capital to shareholders. In 2025, they deployed $1 billion in share repurchases and $32 million in dividends alongside M&A spending. This 'durable free cash flow' generation supports a balanced capital deployment strategy that rewards shareholders while investing in high-return growth opportunities, reinforcing the 'value creation flywheel' thesis.
The 2026 guidance implies a significant deceleration in organic growth to just 1% at the midpoint, with Q1 specifically expected to be 'flat to maybe very slightly down.' Management attributed this to normal seasonality and the lack of a market recovery baked in, but such low organic growth raises concerns about the company's ability to drive top-line expansion without heavy reliance on M&A, especially as tough comps from the prior year's first half persist.
Tariff impacts are explicitly cited as a headwind to margins in the first half of 2026, with management expecting price/cost to be only 'neutral' in H1 before turning positive in H2. This suggests near-term margin pressure, particularly in the ITS segment, which saw margins decline in Q4 due to these dilutive effects. The need to offset these costs with pricing actions in a potentially slowing demand environment creates execution risk.
Management noted that while the long-cycle project funnel is active, 'elongation' in customer decision-making persists. This delay in converting funnels to orders could impact revenue visibility, particularly in the PST segment's aerospace and defense business, which saw orders down due to timing. If these delays extend further, it could dampen the expected recovery in the second half of the year.
Free cash flow conversion guidance is set at approximately 95%, slightly below the 100%+ levels often targeted by top-tier industrials. While management cited working capital efficiency and inventory builds related to tariffs as the primary drag, any inability to optimize working capital in the second half could result in a cash flow shortfall relative to investor expectations.
Overall: Management displayed a tone of disciplined confidence and resilience, emphasizing 'self-help' strategies and operational execution over reliance on macroeconomic improvements. While acknowledging tariff headwinds and cautious end markets, executives expressed strong conviction in their M&A flywheel, recurring revenue initiatives, and the agility of their teams (IRX) to outperform regardless of broad market conditions.
Confidence: HIGH - Management consistently beat the upper end of their guidance ranges and articulated clear, specific drivers for future growth (M&A pipeline, recurring revenue backlog). Their confidence was rooted in internal controllables rather than external factors, with Vicente Reynal explicitly stating they are 'not embedding any market recovery' in the 2026 guide, suggesting a prudent but solid baseline.
2.5% - 4.5% (1% organic at midpoint)
$2.13 billion - $2.19 billion
$3.45 - $3.57 (~5% growth at midpoint)
~95%
Flat to slightly down
Hedging & Uncertainty: Management frequently used temporal and probability hedges to frame their outlook without overcommitting. Phrases like 'cautiously optimistic,' 'too early to call a meaningful inflection,' and 'prudent approach' were used to describe macroeconomic signals such as the PMI. They also used qualifiers regarding the guidance, stating it assumes 'current trajectory continues' rather than a recovery. This hedging suggests management is aware of the fragile macro environment and prefers to under-promise to ensure delivery, a pattern consistent with their history of beating guidance.
We are cautiously optimistic about the improving trends moving into 2026. - Vicente Reynal, Chairman and CEO
We are not embedding any market recovery here. - Vicente Reynal, Chairman and CEO
We expect to see a relatively even earnings growth on a quarterly basis. - Vikram U. Kini, Chief Financial Officer
The acquisition pipeline remains robust. - Vicente Reynal, Chairman and CEO
We are seeing some pickup in the short cycle clearly. - Vicente Reynal, Chairman and CEO
We do not expect anything here to be dramatically different. - Vikram U. Kini, Chief Financial Officer
Analyst Sentiment: Analysts were generally inquisitive about the sustainability of growth, specifically pressing on the low organic growth guidance and the timing of a macro recovery. Questions focused heavily on the 'price/cost' dynamics, the specific drivers of the China turnaround, and the M&A pipeline.
Management Responses: Management responses were consistent and disciplined, frequently reiterating that the guidance does not rely on a market recovery. They provided detailed color on segment performance (ITS vs. PST) and defended the conservative organic growth outlook by pointing to the 'self-help' nature of their recent wins and the lack of broad-based demand improvement.
Discussion on the 'price/cost' environment, with management confirming tariff headwinds in H1 but expecting neutrality in H1 and expansion in H2.
Deep dive into the China performance, where management clarified that growth is driven by new product launches and localization rather than macro improvement.
Inquiries into the M&A pipeline, with management confirming a robust funnel of 'bolt-on' deals with attractive multiples.
Questions regarding the margin profile of recurring revenue, confirmed to be 'north of 60%' though currently reinvesting for growth.
Ingersoll Rand remains a high-quality industrial compounder with a proven track record of margin expansion and disciplined capital allocation. The company's 'value creation flywheel'—driven by M&A and recurring revenue—provides a solid foundation for long-term growth. However, the conservative 2026 guidance, which calls for only 1% organic growth and faces tariff headwinds in the first half, suggests limited near-term catalysts. While the 'self-help' strategy in China and Life Sciences is encouraging, the stock appears fairly valued at current levels, requiring a clearer sign of a broad industrial upturn or sustained double-digit organic growth to warrant a more aggressive rating. Investors should wait for evidence of margin expansion in the second half or a larger-than-expected contribution from the M&A pipeline before adding to positions.
Management noted that while the U.S. PMI recently turned above 50, it is 'too early to call a meaningful inflection' after 38 months below 50. They are guiding based on current run-rates rather than a recovery.
Despite a challenging macro environment in China, IR is gaining share through localization and new product launches, achieving three consecutive quarters of organic order growth.
Tariffs continue to be a headwind, specifically impacting margins in the first half of 2026. Management is implementing pricing actions to offset this but expects H1 price/cost to be neutral.
The Life Sciences end market remains a bright spot, with mid-teens organic order growth in Q4 driven by biopharma production and U.S. reshoring of drug discovery.